Journals / Retina-Vitreus / 2010 / Cilt: 18 - Sayı: 4

Treatment of dry age-related macular degeneration

Kuru tip yaşa bağlı makula dejeneresansı tedavisi

Pages
253–262
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Along with these, there will be new treatment alternatives together with the developments related to pathophysiology, immunology and genetic sciences.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Age related macular degeneration (ARMD) is the third most common reason for legally blindness in the world.
📊
Key Findings & Data:It is known that it currently exists between 30 and 50 million people around the world and is estimated that will have doubled by the end of the coming decade.
💡
Conclusion & Impact:Along with these, there will be new treatment alternatives together with the developments related to pathophysiology, immunology and genetic sciences.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Age related macular degeneration (ARMD) is the third most common reason for legally blindness in the world. It is known that it currently exists between 30 and 50 million people around the world and is estimated that will have doubled by the end of the coming decade. It is important to know the relation between changeable risk factors of ARMD, which are smoking, diet, obesity, systemic diseases and environmental factors and the disease is important in terms of preventing and decreasing the progression in the disease. Another risk factor is the fact that the necessary dietary supplements can not be consumed in certain diets. Lack of antioxidants like lutein, zeaxanthin, cryptoxanthin, alpha-carotene, and beta-carotene together with vitamins C, D, E, and zinc, copper, selenium, magnesium trace minerals play a role in ARMD pathogenesis. In order to prevent or decrease the progression in ARMD and to live a healthy life, people especially over 55 years should be suggested to keep away from sunlight, a life without smoking, regular physical activity, controlled weight, blood pressure and cholesterol, decreased fat and sugar consumption and cunsumption of green vegetables, walnut and fruit, together with fish once or twice a week. If ARMD is diagnosed in an early stage, 10mg/day lutein and 500-1000 mg/day omega-3 intake is suitable. If there is advanced stage ARMD in one eye, intense antioxidan supplement may be thought about as mentioned in AREDS studies. Antioxidant, vitamin and mineral supplements are good in terms of protecting the other eye, but it should be kept in mind that these treatments also have their side effects. Laser treatment in eyes with drusen, Rheopheresis, Implantable miniature telescope and macular translocation have been tried for ARMD treatment; however, have not proved effective. Research on Glatiramer Acetate (Vaccination With Copaxone), Fenretinide, Eculizumab (Soliris), ARC1905 (Anti-C5 Aptamer), RN6G, Photobiomodulation, OT-551 and AL-8309B Antioxidant Eye Drops, Sirolimus (Rapamycin), Encapsulated Cell Technology Implant (Cilier Nörotrofik Faktör) ve RPE Transplantation (Retinal Replacement Therapy) is still being conducted. Along with these, there will be new treatment alternatives together with the developments related to pathophysiology, immunology and genetic sciences.

Özet

Yaşa bağlı makula dejeneresansı (YBMD) dünyada yasal körlük nedenleri içinde 3. sırada yer almaktadır. Halen dünyada 30-50 milyon kişide var olduğu bildirilen YBMD’lı hasta sayısının gelecek dekatta iki katına çıkması beklenmektedir. YBMD’nın değiştirilebilir risk faktörleri olan sigara, beslenme, obesite, sistemik hastalıklar ve çevresel faktörler ile ilişkisinin iyi bilinmesi, hastalıktan korunma ve ilerlemesini azaltma yönünden önem taşımaktadır. Ayrıca gerekli besinlerin diyetle alınamaması da risk faktörlerinden biridir. Diyetle alınması gereken Vitamin C, D, E, selenyum, çinko, bakır, magnezyum eser mineralleri ile a ve ß karoten, kriptoksantin, lutein ve zeaksantin gibi antioksidanların eksikliği YBMD patogenezinde rol oynamaktadır. YBMD’nın önlenmesi ve ilerlemesinin yavaşlatılması için risk faktörleri de göz önüne bulundurularak sağlıklı bir yaşam biçimi sürdürmek, özellikle 55 yaşın üzerindeki sağlıklı bireylere direkt güneş ışığından korunma, sigarasız yaşam, düzenli egzersiz, kilo, tansiyon ve kolesterol kontrolü, yağı ve şekeri azaltıp, koyu yeşil yapraklı sebzeler, ceviz ve meyve yanı sıra haftada 1-2 kez balık tüketmeleri önerilmelidir. Ancak erken evre YBMD saptandığında 10 mg/gün lutein ve 500-1000 mg/gün omega 3 alımı uygun görülürken, bir gözde ileri evre YBMD varlığında AREDS çalışmalarında belirlenen yoğun antioksidan desteği gündeme gelebilir. Antioksidan, vitamin ve mineral desteği en azından diğer gözü korumak için yararlı olmasına rağmen destek tedavisinin de yan etkileri olduğu unutulmamalıdır. YBMD tedavisi için drusen üzerine veya grid şeklinde lazer, reoferez, kapsül içi minyatür teleskop ve makula translokasyonu tedavileri denenmiş, ancak yeterli başarı elde edilememiştir. Bu çalışmaların yanı sıra patofizyoloji, immünoloji ve genetik alanında yeni gelişmelere paralel yeni tedavi seçenekleri gündeme gelecektir.

🔖

Cite This Article

YAZAR, Z., ZIRIĞ, H. İ. (2010). Treatment of dry age-related macular degeneration. Retina-Vitreus, Cilt: 18 - Sayı: 4, 253–262. https://ajindex.com/articles/305143

References (15)

  1. # Klein R.: Epidemiology of age-related macular degeneration. In: Penfold PL, Provis JM eds: Macular Degeneration. Germany, Springer-Verlag Berlin Heidelberg, 2005
  2. # Bulletin of the World Health Organization in November, 2004:82,11 # Akbatur HH. Şengün A.: Yaşa bağlı makula dejenerasyonu. Proplast, Ankara. 1998
  3. # Boldt HC, Bressler SB, Fine SL, et al.: Age-related macular degeneration. Curr Opin Ophthalmol. 1990
  4. # Age-Related Eye Disease Study Research Group: Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology, 2000
  5. # Leibowitz HM, Krueger DE, Maunder LR, et al.: The Framingham Eye Study Monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol. 1980
  6. # Bressler NM, Bressler SB, West SK, et al.: The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol. 1989
  7. # Klein R, Rowland M, Haris M.: Third National Health and Nutrition Examination Survey. Racial/ethnic differences in age-related maculopathy. Ophthalmology. 1995
  8. # Bürümcek EY.: Yaşa Bağlı Makula Dejeneresansında Risk Faktörleri. 28. Ulusal Oftalmoloji Kursu
  9. Retina “Güncel Tanı ve Tedavi”. Ankara-Türkiye, 11-13 Nisan 2008:23-28. # Seddon JM, Chen CA.: Epidemiology of age-related macular degeneration. Ed. Ryan SJ, In Retina, 4th Ed., Vol 2, Macular Disease, Philadelphia: Mosby Co. 2006
  10. # Ergin MH, Koçak N.: Yaşa bağlı makula dejeneresansında epidemiyoloji ve etyopatogenez. Türkiye Klinikleri J Surg Med Sci. 2006
  11. # Eong KG.: Risk Factors for Age-Related Macular Degeneration and Choroidal Neovascularization.In: Lim JI, ed. Age related macular degeneration. Informa Healthcare, New York. 2008
  12. # Anderson DH, Mullins RF, Hageman GS, et al.: A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002
  13. # Hyman LG, Lilienfeld AM, Ferris FLI, et al.: Senile macular degeneration: a case-control study. Am J Epidemiol. 1983
  14. # Bhagat N.: Non-exudative Age-related Macular Degeneration. In: Lim JI, ed. Age related macular degeneration. Informa Healthcare, New York. 2008
  15. # Seddon JM, George S, Rosner B, et al.: Progression of ag